{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,22]],"date-time":"2026-11-22T00:05:16Z","timestamp":1795305916282,"version":"4.10.3"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Trygve Gythfeldts Research Foundation"},{"DOI":"10.13039\/501100005416","name":"Norwegian Research Council","doi-asserted-by":"publisher","award":["328657"],"award-info":[{"award-number":["328657"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Patients with gout need to adhere to medication over time to achieve good outcomes. We assessed self-reported adherence to medication with urate lowering therapy (ULT) 5\u2009years after a treat-to-target intervention and studied how non-adherence was related to baseline demographic and disease variables.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients in the NOR-Gout observational study were included after a recent gout flare and serum urate &amp;gt;360\u2009\u00b5mol\/l. Patients [mean age 56.2 (S.D. 13.6), 94.5% males, 17.2% with tophi] attended tight-control visits over one year with escalating urate lowering therapy using a treat-to-target strategy. Five-year follow-up included the Medication Adherence Report Scale (MARS-5) questionnaire (range 5\u201325) for adherence. Flares and SUA target achievement were compared for 5-year adherence to medication.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At 5\u00a0years most of the 163 patients used ULT (95.1%). MARS-5 adherence scores after 5\u2009years were high (median 24, interquartile range 22\u201325). Patients in the lowest MARS-5 quartile had, compared with the highest quartile, more often a flare during the last year of follow-up (33.3% vs 9.5%, P\u2009=\u20090.004) and reached the 5-yr serum urate treatment target less frequently (45.2% vs 87.5%, P\u2009&amp;lt;\u20090.001). Baseline lower age (OR 0.56, 95%CI 0.39\u20130.79), non-European origin (OR 0.22, 95%CI 0.06\u20130.80), lower SF-36 mental health scores (OR 0.94, 95%CI 0.91\u20130.98) and less joint pain during last flare (OR 0.73, 95%CI 0.58\u20130.92) were independent risk factors for non-adherence to medication.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients reported high adherence to medication after 5\u2009years. Non-adherence was related to more flares and less urate target achievement. Younger age and non-European origin were associated with non-adherence.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae514","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T16:47:52Z","timestamp":1726678072000},"page":"1799-1806","source":"Crossref","is-referenced-by-count":14,"title":["Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6881-9552","authenticated-orcid":false,"given":"Till","family":"Uhlig","sequence":"first","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital , Oslo,","place":["Norway"]},{"name":"Faculty of Medicine, University of Oslo , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars F","family":"Karoliussen","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Sexton","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-902X","authenticated-orcid":false,"given":"Sella A","family":"Provan","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital , Oslo,","place":["Norway"]},{"name":"Section for Public Health, Inland Norway University of Applied Sciences , Elverum,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen A","family":"Haavardsholm","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital , Oslo,","place":["Norway"]},{"name":"Faculty of Medicine, University of Oslo , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland , Auckland,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7317-8991","authenticated-orcid":false,"given":"Hilde Berner","family":"Hammer","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital , Oslo,","place":["Norway"]},{"name":"Faculty of Medicine, University of Oslo , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"key":"2025041415170023900_keae514-B1","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","article-title":"Gout","volume":"397","author":"Dalbeth","year":"2021","journal-title":"Lancet"},{"key":"2025041415170023900_keae514-B2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025041415170023900_keae514-B3","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/rheumatology\/kex150","article-title":"The British Society for Rheumatology Guideline for the Management of Gout","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2025041415170023900_keae514-B4","doi-asserted-by":"crossref","first-page":"i51","DOI":"10.1093\/rheumatology\/kex421","article-title":"Education and non-pharmacological approaches for gout","volume":"57","author":"Abhishek","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2025041415170023900_keae514-B5","doi-asserted-by":"crossref","first-page":"e017542","DOI":"10.1136\/bmjopen-2017-017542","article-title":"Rate of adherence to urate-lowering therapy among patients with gout: a systematic review and meta-analysis","volume":"8","author":"Yin","year":"2018","journal-title":"BMJ Open"},{"key":"2025041415170023900_keae514-B6","doi-asserted-by":"crossref","first-page":"100416","DOI":"10.1016\/j.lanepe.2022.100416","article-title":"Management of gout following 2016\/2017 European (EULAR) and British (BSR) guidelines: an interrupted time-series analysis in the United Kingdom","volume":"18","author":"Russell","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"2025041415170023900_keae514-B7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13075-016-1062-6","article-title":"Incidence and prevalence of gout in Western Sweden","volume":"18","author":"Dehlin","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025041415170023900_keae514-B8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","article-title":"Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study","volume":"74","author":"Kuo","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025041415170023900_keae514-B9","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1001\/jama.2014.14484","article-title":"Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England","volume":"312","author":"Kuo","year":"2014","journal-title":"Jama"},{"key":"2025041415170023900_keae514-B10","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/BOR.0000000000000774","article-title":"Adherence to gout guidelines: where do we stand?","volume":"33","author":"Ho","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"2025041415170023900_keae514-B11","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s40744-020-00249-w","article-title":"High rate of adherence to urate-lowering treatment in patients with gout: who's to blame?","volume":"7","author":"Perez-Ruiz","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2025041415170023900_keae514-B12","first-page":"529","article-title":"Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care-5-year follow-up of a proof-of-concept study","volume":"56","author":"Abhishek","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2025041415170023900_keae514-B13","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A new taxonomy for describing and defining adherence to medications","volume":"73","author":"Vrijens","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"2025041415170023900_keae514-B14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/08870440290001502","article-title":"Self-regulation and Self-management in Asthma: exploring The Role of Illness Perceptions and Treatment Beliefs in Explaining Non-adherence to Preventer Medication","volume":"17","author":"Horne","year":"2002","journal-title":"Psychology & Health"},{"key":"2025041415170023900_keae514-B15","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2147\/PPA.S119719","article-title":"Utility of the morisky medication adherence scale in gout: a prospective study","volume":"10","author":"Tan","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"2025041415170023900_keae514-B16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jpsychores.2018.10.010","article-title":"The Intentional Non-Adherence Scale (INAS): initial development and validation","volume":"115","author":"Weinman","year":"2018","journal-title":"Journal of psychosomatic research"},{"key":"2025041415170023900_keae514-B17","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001628","article-title":"12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target","volume":"7","author":"Uhlig","year":"2021","journal-title":"RMD Open"},{"key":"2025041415170023900_keae514-B18","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","article-title":"2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"74","author":"Neogi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025041415170023900_keae514-B19","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/bcp.14193","article-title":"The Medication Adherence Report Scale: a measurement tool for eliciting patients' reports of nonadherence","volume":"86","author":"Chan","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2025041415170023900_keae514-B20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/JCP.0b013e3181d2191e","article-title":"Medication adherence in outpatients with severe mental disorders: relation between self-reports and serum level","volume":"30","author":"J\u00f3nsd\u00f3ttir","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"2025041415170023900_keae514-B21","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/art.10993","article-title":"The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research","volume":"49","author":"Sangha","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2025041415170023900_keae514-B22","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.3899\/jrheum.110271","article-title":"Patient-reported outcomes in chronic gout: a report from OMERACT 10","volume":"38","author":"Singh","year":"2011","journal-title":"J Rheumatol"},{"key":"2025041415170023900_keae514-B23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"2025041415170023900_keae514-B24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/00207411.1994.11449283","article-title":"The SF-36 Health Survey: development and use in mental health research and the IQOLA project","volume":"23","author":"Ware","year":"1995","journal-title":"Int J Ment Health"},{"key":"2025041415170023900_keae514-B25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"2025041415170023900_keae514-B26","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1136\/annrheumdis-2020-217392","article-title":"Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study","volume":"79","author":"Hammer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025041415170023900_keae514-B27","doi-asserted-by":"crossref","first-page":"SI81","DOI":"10.1093\/rheumatology\/keab533","article-title":"Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study","volume":"61","author":"Uhlig","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025041415170023900_keae514-B28","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/bcp.16016","article-title":"Estimation of adherence to urate-lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient-reported dosing","volume":"90","author":"Schulz","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"2025041415170023900_keae514-B29","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1080\/14397595.2018.1483293","article-title":"Long-term adherence and persistence with febuxostat among male patients with gout in a routine clinical setting","volume":"29","author":"Lee","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2025041415170023900_keae514-B30","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3899\/jrheum.220270","article-title":"Long-term follow-up of a randomized controlled trial of allopurinol dose escalation to achieve target serum urate in people with gout","volume":"49","author":"Coleman","year":"2022","journal-title":"J Rheumatol"},{"key":"2025041415170023900_keae514-B31","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1001\/jama.1993.03500210079036","article-title":"Is this patient taking the treatment as prescribed?","volume":"269","author":"Stephenson","year":"1993","journal-title":"JAMA"},{"key":"2025041415170023900_keae514-B32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1891\/1061-3749.20.1.59","article-title":"Psychometric properties of three medication adherence scales in patients with rheumatoid arthritis","volume":"20","author":"Salt","year":"2012","journal-title":"J Nurs Meas"},{"key":"2025041415170023900_keae514-B33","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s10067-016-3182-4","article-title":"Determinants of methotrexate adherence in rheumatoid arthritis patients","volume":"35","author":"De Cuyper","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2025041415170023900_keae514-B34","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3390\/medicina59081446","article-title":"Assessment and prediction of adherence to methotrexate using three self-report questionnaires in patients with rheumatoid arthritis","volume":"59","author":"Ceranic","year":"2023","journal-title":"Medicina"},{"key":"2025041415170023900_keae514-B35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/ibd\/izaa056","article-title":"Utility of the MARS-5 in Assessing Medication Adherence in IBD","volume":"27","author":"Stone","year":"2021","journal-title":"Inflammatory bowel diseases"},{"key":"2025041415170023900_keae514-B36","doi-asserted-by":"crossref","first-page":"111472","DOI":"10.1016\/j.jpsychores.2023.111472","article-title":"The impact of trust in healthcare and medication, and beliefs about medication on medication adherence in a Dutch medication-using population","volume":"174","author":"Te Paske","year":"2023","journal-title":"Journal of psychosomatic research"},{"key":"2025041415170023900_keae514-B37","article-title":"What are the factors associated with nonadherence to medications in patients with chronic diseases?","volume":"9","author":"Al Bawab","year":"2021","journal-title":"Healthcare (Basel)"},{"key":"2025041415170023900_keae514-B38","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/08870446.2019.1672873","article-title":"Psychological predictors of adherence to oral hypoglycaemic agents: an application of the ProMAS questionnaire","volume":"35","author":"Vluggen","year":"2020","journal-title":"Psychol Health"},{"key":"2025041415170023900_keae514-B39","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/02770903.2016.1180699","article-title":"Is the MARS questionnaire a reliable measure of medication adherence in childhood asthma?","volume":"53","author":"Garcia-Marcos","year":"2016","journal-title":"J Asthma"},{"key":"2025041415170023900_keae514-B40","doi-asserted-by":"crossref","first-page":"e003551","DOI":"10.1136\/bmjopen-2013-003551","article-title":"The association between patients' beliefs about medicines and adherence to drug treatment after stroke: a cross-sectional questionnaire survey","volume":"3","author":"Sj\u00f6lander","year":"2013","journal-title":"BMJ Open"},{"key":"2025041415170023900_keae514-B41","doi-asserted-by":"crossref","first-page":"105435","DOI":"10.1016\/j.jbspin.2022.105435","article-title":"Palpable tophi and more comorbidities associated with adherence to urate-lowering medical therapy in a Chinese gout cohort","volume":"89","author":"Hu","year":"2022","journal-title":"Joint Bone Spine"},{"key":"2025041415170023900_keae514-B42","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.3346\/jkms.2021.36.e208","article-title":"Patient Perspectives and Preferences Regarding Gout and Gout Management: Impact on Adherence","volume":"36","author":"Chung","year":"2021","journal-title":"J Korean Med Sci"},{"key":"2025041415170023900_keae514-B43","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1016\/S2665-9913(20)30029-1","article-title":"Allopurinol adherence and its predictors in gout: a national cohort study in US veterans","volume":"2","author":"Singh","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2025041415170023900_keae514-B44","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2147\/TCRM.S162956","article-title":"Improving adherence to gout therapy: an expert review","volume":"14","author":"Perez-Ruiz","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"2025041415170023900_keae514-B45","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s12891-016-1117-5","article-title":"A joint effort over a period of time: factors affecting use of urate-lowering therapy for long-term treatment of gout","volume":"17","author":"Richardson","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"2025041415170023900_keae514-B46","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/art.40381","article-title":"Brief Report: validation of a Definition of Flare in Patients With Established Gout","volume":"70","author":"Gaffo","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025041415170023900_keae514-B47","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3899\/jrheum.2023-0711","article-title":"Can smartphone notifications help with gout management? A feasibility study","volume":"51","author":"Emad","year":"2024","journal-title":"J Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae514\/60658338\/keae514.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/4\/1799\/60658338\/keae514.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/4\/1799\/60658338\/keae514.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T15:17:13Z","timestamp":1744643833000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/4\/1799\/7760225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,9,18]]},"published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae514","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,9,18]]}}}